NPR2 Antibody

What is NPR2 and what are its key characteristics?

NPR2 (Natriuretic Peptide Receptor 2) is a transmembrane receptor that plays a central role in growth development and bone morphogenesis. It functions as a receptor for C-type natriuretic peptide (CNP) and generates cyclic guanosine monophosphate (cGMP) when activated. The protein exists in both immature (endoplasmic reticulum-located) and mature (plasma membrane) forms that can be distinguished by their glycosylation patterns . Loss-of-function variations in the NPR2 gene have been associated with skeletal dysplasias and short stature, with the severity of the phenotype often correlating with the functional impact of the variant .

What applications are NPR2 antibodies commonly used for?

NPR2 antibodies are utilized in multiple research applications, including:

• Flow cytometry for detection of NPR2 in transfected cells

• Immunofluorescence to study subcellular localization of NPR2 and its variants

• Western blotting to evaluate expression patterns and glycosylation profiles

• Immunoprecipitation assays to isolate NPR2 for downstream enzymatic analyses

• Investigating trafficking defects in NPR2 variants associated with skeletal dysplasias

Each application requires specific optimization of antibody dilutions and experimental conditions for optimal results.

How can I validate the specificity of an NPR2 antibody?

To validate NPR2 antibody specificity, consider implementing this multi-step approach:

• Positive and negative controls: Use HEK293 cells transfected with human NPR2 as a positive control and untransfected cells as a negative control .

• Isotype control comparison: Include an appropriate isotype control (e.g., Mouse IgG2A) alongside your NPR2 antibody to identify non-specific binding .

• Secondary antibody validation: Ensure your secondary antibody (e.g., Allophycocyanin-conjugated Anti-Mouse IgG) works properly with minimal background .

• Expression system validation: If possible, use a dual-marker system such as co-transfection with eGFP to identify transfected cells and confirm antibody specificity .

• Western blot analysis: Confirm antibody specificity by detecting the expected molecular weight bands (~130-140 kDa for NPR2) .

What cell models are recommended for NPR2 antibody studies?

Based on the research literature, these cell models have proven effective for NPR2 antibody research:

When selecting a cell model, consider the specific application and the endogenous expression levels of NPR2 in your chosen cell line to avoid interference with your experimental readouts.

How do NPR2 missense variants affect protein trafficking and localization?

NPR2 missense variants exhibit distinct trafficking patterns that correlate with their functional impact and clinical manifestations. Through subcellular localization studies, these variants can be categorized into trafficking-competent and trafficking-defective groups:

Trafficking-defective variants (e.g., p.Leu51Pro, p.Gly123Val, p.Leu314Arg, and p.Arg388Gln):

• Show exclusive retention in the endoplasmic reticulum (ER)

• Display only the lower molecular weight immature band (~130 kDa) in immunoblotting

• Demonstrate quantitative sensitivity to Endoglycosidase H (Endo H), confirming their immature status

• Likely undergo ER-associated degradation (ERAD)

Partially trafficking-competent variants (e.g., p.Arg495Cys, p.Arg557His, and p.Arg932Cys):

• Show both ER retention and partial plasma membrane localization

• Display both immature (~130 kDa) and mature (~140 kDa) bands, with greater proportion of immature forms compared to wild-type

• Exhibit partial resistance to Endo H digestion

Trafficking-competent variants (e.g., p.Arg318Gly):

• Display trafficking patterns similar to wild-type NPR2

• Show both mature and immature bands in proportions comparable to wild-type

To investigate these differences, co-localization studies with appropriate markers (HRas for plasma membrane, Calnexin for ER) are essential for accurate classification of variant trafficking behaviors .

What methods can be used to assess NPR2 glycosylation profiles?

NPR2 glycosylation profiles provide crucial information about protein maturation and trafficking. The following methodological approach is recommended:

• Sample preparation:

  • Express HA-tagged wild-type and variant NPR2 in HEK293T cells

  • Harvest cells 48 hours post-transfection

  • Perform immunoprecipitation using anti-HA epitope agarose resins

• Enzymatic digestion:

  • PNGase F treatment: Removes all N-linked oligosaccharides regardless of complexity

    • Denature samples in denaturation buffer at 100°C

    • Add reaction buffer and PNGase F enzyme

    • Incubate for 3 hours at 37°C

  • Endoglycosidase H (Endo H) treatment: Digests only high-mannose and some hybrid N-linked glycans (immature ER forms)

    • Denature samples in denaturation buffer at 100°C

    • Add reaction buffer and Endo H enzyme

    • Incubate for 1 hour at 37°C

• Analysis:

  • Resolve treated samples by SDS-PAGE

  • Perform immunoblotting with anti-HA antibody

  • Compare band patterns to interpret glycosylation status:

    • Complete shift to lower molecular weight with PNGase F confirms N-glycosylation

    • Shift of only the lower band with Endo H confirms ER retention of that fraction

    • Resistance to Endo H of the upper band confirms Golgi processing and maturation

This approach allows for precise discrimination between immature ER-located NPR2 and mature post-ER forms, providing insights into trafficking defects of NPR2 variants.

How can cyclic GMP production be measured to assess NPR2 functionality?

Functional assessment of NPR2 variants requires measurement of cyclic GMP (cGMP) production in response to C-type natriuretic peptide (CNP) stimulation. This methodology enables quantitative evaluation of receptor activity:

• Cell preparation and transfection:

  • Seed HEK293T cells in 12-well plates

  • Transfect with HA-tagged wild-type or variant NPR2 plasmids

  • Allow 48 hours for protein expression

• CNP stimulation:

  • Prepare C-natriuretic peptide (CNP) solution (100 nM) in serum-free DMEM

  • Treat transfected cells with CNP for 10 minutes at 37°C

  • Add 0.1 M HCl to stop phosphodiesterase activity and stabilize cGMP

  • Incubate for 10 minutes at room temperature

• cGMP measurement:

  • Collect cell lysates

  • Perform Enzyme-Linked Immunosorbent Assay (ELISA) specific for cGMP

  • Calculate cGMP concentrations using a standard curve

  • Normalize results to protein concentration or expression levels of NPR2

• Data interpretation:

  • Compare cGMP production levels between wild-type and variant NPR2

  • Correlate functional deficits with trafficking abnormalities

  • Assess relationship between biochemical phenotype and clinical manifestations

This assay provides critical information about the signaling capacity of NPR2 variants and helps distinguish between trafficking defects and intrinsic functional impairments.

What approaches can be used to design antibodies with specific binding profiles to NPR2?

Designing antibodies with customized specificity profiles for NPR2 requires sophisticated computational and experimental approaches:

• High-throughput phage display selection:

  • Create diverse antibody libraries

  • Perform selections against NPR2 or its variants

  • Sequence selected antibodies using high-throughput sequencing

  • Analyze enrichment patterns to identify binding determinants

• Biophysics-informed computational modeling:

  • Develop models that associate distinct binding modes with specific ligands

  • Train models on experimentally selected antibodies

  • Use the models to predict outcomes for new ligand combinations

  • Generate novel antibody variants with desired specificity profiles

• Mode disentanglement approach:

  • Identify different binding modes associated with particular ligands

  • Train models to distinguish between these modes

  • Predict antibody specificity against unseen targets

  • Design antibodies with either specific high affinity for particular targets or cross-specificity for multiple targets

• Experimental validation:

  • Test computationally designed antibodies in binding assays

  • Verify specificity against different epitopes or variants of NPR2

  • Refine models based on experimental feedback

This integrated approach leverages both experimental data and computational predictions to design antibodies that can specifically recognize NPR2 or discriminate between its different variants, which is particularly valuable for research on NPR2-related disorders.

How do I troubleshoot inconsistent NPR2 antibody staining in immunofluorescence experiments?

Inconsistent staining in NPR2 immunofluorescence experiments can arise from multiple factors. This systematic troubleshooting approach addresses common issues:

• Fixation and permeabilization optimization:

  • Compare different fixatives (paraformaldehyde, methanol, acetone)

  • Test various permeabilization agents (Triton X-100, saponin, digitonin)

  • Optimize incubation times for each step

  • For NPR2, which has both membrane and intracellular forms, fixation conditions may significantly affect epitope accessibility

• Antibody validation and controls:

  • Include positive controls (cells transfected with NPR2)

  • Use appropriate negative controls (untransfected cells, isotype controls)

  • Perform co-localization with known markers:

    • HRas for plasma membrane localization

    • Calnexin for endoplasmic reticulum localization

• Signal amplification strategies:

  • Test tyramide signal amplification for weak signals

  • Optimize antibody concentrations through titration

  • Compare different detection systems (direct vs. indirect immunofluorescence)

  • Consider using tagged NPR2 (HA-tag) for consistent detection

• Image acquisition parameters:

  • Standardize exposure times and gain settings

  • Use appropriate filters to minimize autofluorescence

  • Consider confocal microscopy for improved signal-to-noise ratio

  • For NPR2, use oil immersion objectives (×100) for optimal resolution of subcellular structures

• Expression level considerations:

  • Control transfection efficiency using co-transfected markers (e.g., eGFP)

  • Be aware that overexpression may cause artificial retention in the ER even for wild-type NPR2

  • Consider inducible expression systems for more physiological expression levels

By systematically addressing these factors, researchers can achieve more consistent and reliable immunofluorescence results when studying NPR2 localization and trafficking.

What controls should be included when studying NPR2 variants?

When investigating NPR2 variants, a comprehensive set of controls is essential for valid interpretation of results:

• Expression controls:

  • Wild-type NPR2 as positive control

  • Empty vector as negative control

  • GAPDH or other housekeeping proteins as loading controls for Western blots

  • GFP co-transfection to monitor transfection efficiency

• Subcellular localization controls:

  • Plasma membrane markers (e.g., GFP-tagged HRas)

  • Endoplasmic reticulum markers (e.g., Calnexin)

  • Golgi markers (e.g., GM130) if trafficking is being assessed

• Glycosylation analysis controls:

  • Untreated samples as baseline

  • PNGase F-treated samples to confirm N-glycosylation

  • Endo H-treated samples to distinguish ER-retained from mature forms

  • Mock (untransfected) samples to identify non-specific bands

• Functional assay controls:

  • Unstimulated cells as baseline for cGMP production

  • Dose-response curves for CNP stimulation

  • Positive controls (e.g., direct activators of guanylyl cyclase)

  • Negative controls (e.g., inhibitors of guanylyl cyclase)

Implementing these controls ensures that observed differences between wild-type and variant NPR2 are attributable to the variants themselves rather than experimental artifacts.

How can I design experiments to correlate NPR2 variant functional defects with clinical phenotypes?

To establish meaningful correlations between NPR2 variant functional defects and clinical phenotypes, consider this multi-layered experimental approach:

• Comprehensive functional characterization:

  • Assess multiple aspects of NPR2 biology:

    • Expression levels and stability

    • Subcellular trafficking and localization

    • Glycosylation profiles

    • cGMP production in response to CNP

  • Quantify the severity of defects for each functional parameter

• Genotype-phenotype correlation analysis:

  • Collect detailed clinical data from patients with NPR2 variants

  • Document phenotypic features (height, bone abnormalities, etc.)

  • Compare homozygous versus heterozygous manifestations

  • Calculate correlation coefficients between functional parameters and clinical severity

• Structure-function relationship studies:

  • Map variants onto the NPR2 protein structure

  • Group variants by domain location (e.g., extracellular, kinase homology, guanylyl cyclase)

  • Analyze whether variants in specific domains correlate with particular functional defects

  • Use computational modeling to predict structural impacts of variants

• Rescue experiments:

  • Test chemical chaperones for trafficking-defective variants

  • Evaluate pharmacological enhancement of residual activity

  • Assess temperature sensitivity of variant folding and trafficking

  • These approaches can provide insights into potential therapeutic strategies

• Animal models:

  • Generate knock-in models of selected NPR2 variants

  • Compare phenotypes across species

  • Evaluate tissue-specific effects of variants

  • Test potential therapeutic interventions

This integrated approach enables more precise correlations between molecular defects and clinical manifestations, potentially informing personalized therapeutic strategies for patients with NPR2-related disorders .